Single-Dose of H1N1 Vaccine Elicits Strong Immune Response in Children: Presented at ESPID
Unregistered User
If this is not your name, click here.
Contact Us | Order Now | Journals | Bookstore | Register a colleague
 
  SEARCH  
News
Bookstore
Medline
The Web
Meetings & Congresses
Complete Doctor's Guide
 


 EXPLORE :
 news  All News
 webcasts All Webcasts
 All cases All Cases
 Meetings All Meetings & Congresses
 Medical All Medical Resources

top





New drugs / indications

English Dictionary

Medical Dictionary

Thesaurus



Warning | Privacy | Awards



 Favourite Journals 

Click here to choose your favourite journals


 Favourite Sites 

Click here to choose your favourite sites


 Languages 



  




Single-Dose of H1N1 Vaccine Elicits Strong Immune Response in Children: Presented at ESPID

By Jenny Powers

NICE, France -- May 12, 2010 -- A single dose of monovalent influenza A (H1N1) vaccine in both adjuvanted (MF59) and non-adjuvanted forms elicit a strong immune response within 3 weeks in children aged 3 to <9 years, researchers reported here at the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID).

Matthew Hohenboken, MD, Novartis Vaccines and Diagnostics, Cambridge, Massachusetts, presented interim results of a study here on May 7.

A total of 1,254 healthy children were randomised to receive intramuscular H1N1 vaccine injections (day 1 and 22) formulated with 3.75, 7.5, 15, or 30 mcg of antigen, with or without adjuvant.

Interim immunogenicity (by haemagglutination inhibition [HI] assay) and seroconversion rate were evaluated on day 22.

The baseline seropositivity (HI titre >=10) rates in each group were comparable (18%-27%) and all adjuvanted groups satisfied the HI titre >=1:40 criteria after 1 dose. However, the non-adjuvanted groups met these criteria only after 2 doses.

Children in all vaccine groups -- except the group that received 7.5 mcg without adjuvant -- satisfied the seroconversion criterion (prevaccination HI titre < 1:10 and post-vaccination titre >=1:40 or prevaccination HI titre >=1:10 and >=4-fold rise in postvaccination titre).

All adjuvanted vaccines (3.75, 7.5, and 15 mcg antigen content) were superior to all non-adjuvanted vaccines.

One episode of febrile convulsion was reported on day 4 post vaccination in the adjuvanted group. No other noteworthy difference in frequency or type of adverse events was observed between groups.

Funding for this study was provided by Novartis.

[Presentation title: An Adjuvanted and Non-Adjuvanted Egg-Derived, Inactivated A/H1N1 Monovalent Subunit Influenza Vaccine in Children 3 to <9 Years of Age. Abstract 520]


E-mail this page
to a friend or colleague!
To print,
use this version




Any question regarding a medical diagnosis, treatment, referral, drug availability or pricing should be directed to either a licensed physician or to the product's manufacturer.

If you have any technical questions or other concerns about this site, feel free to contact us at webmaster@docguide.com.

All contents Copyright (c) 1995- Doctor's Guide Publishing Limited. All rights reserved.


Employment opportunities | Partnering opportunities